Clinical Trials Logo

Sleepiness clinical trials

View clinical trials related to Sleepiness.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04618263 Terminated - Clinical trials for Major Depressive Disorder

Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers

Start date: October 26, 2020
Phase: Phase 1
Study type: Interventional

To evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of GATE-101 in normal human volunteers

NCT ID: NCT03879044 Terminated - Clinical trials for Shift-Work Sleep Disorder

Transcranial Direct Current Stimulation Therapy for Sleepiness Related to Shift Work Disorder (tDCS-SWORD)

tDCS-SWORD
Start date: March 20, 2019
Phase: N/A
Study type: Interventional

1. To determine the effects of tDCS on subjective measures of sleepiness in night-shift workers with shift work disorder. 2. To determine the effects of transcranial direct current stimulation (tDCS) on vigilance in night-shift workers with shift work disorder.

NCT ID: NCT00983437 Terminated - Clinical trials for Traumatic Brain Injury

Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

Start date: August 31, 2009
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the safety and tolerability of long-term (12 months) armodafinil treatment in patients with excessive sleepiness associated with mild or moderate closed traumatic brain injury (TBI).

NCT ID: NCT00911053 Terminated - Insomnia Clinical Trials

Melatonin for Circadian Sleep Disorders in the Blind

Start date: June 1997
Phase: N/A
Study type: Interventional

This research project consists of a three part study with five embedded sub studies. The first study phase identifies "body rhythms" of sleepiness/wakefulness and of melatonin levels for each subject (including sub-study 1). The second study phase identifies the optimum dose and timing of melatonin for regulating each individual's 24-hour sleep/waking cycle (including sub-study 2). The third study phase introduces a new independent variable, light (including sub-studies 3 and 4). Sub-study 5 is an optional longitudinal study. Sub-study 1 looks at how keeping a regular sleep schedule affects the body's natural rhythm. Sub-study 2 looks at how individuals metabolize melatonin. Sub-study 3 tests how individuals' endogenous melatonin production responds to bright outdoor light and Sub-study 4 tests a previous finding that artificial bright light exposed daily behind the knee can regulate the body clock. Sub-study 5 is an optional longitudinal study, an extension of the first study stage, for subjects whose rhythms are not clearly free-running.

NCT ID: NCT00893789 Terminated - Clinical trials for Traumatic Brain Injury

Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

Start date: April 30, 2009
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to determine whether armodafinil treatment is more effective than placebo treatment in patients with excessive sleepiness associated with mild or moderate closed traumatic brain injury (TBI).